New neglected disease collaboration between DNDi and Takeda

5 April 2018

Japan’s Takeda Pharmaceutical (TYO: 4502) has entered into a new collaboration with the Drugs for Neglected Diseases initiative (DNDi) related to preclinical and Phase I clinical studies into candidates to treat visceral leishmaniasis (VL).

Founded in 2003, DNDi is a Geneva, Switzerland-based non-profit which conducts its own clinical development programs drawing from a mix of public and private donations. The group has a pipeline of over 30 projects targeting some of the world’s most neglected diseases.

The collaboration with Takeda will see research undertaken into drug candidate compounds that have been discovered among the aminopyrazole compound class.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK